Law Alan Siems 4

What Happened
Alan Siems, listed as a Director and noted as Chief Clinical Officer - Specialty Practices, received a grant of 7,796 restricted stock units (RSUs) on June 15, 2026. The RSUs were granted for no cash consideration (value recorded as $0 on the Form 4) and are derivative awards that convert to common shares upon vesting.

Key Details

• Transaction date: 2026-06-15; Filing date: 2026-06-22. (Filing occurred 7 days after the transaction.)
• Award type: Restricted Stock Units (derivative award), 7,796 RSUs; reported price $0.00 (granted for no cash consideration).
• Vesting: 25% of the RSUs vest on each of the first four anniversaries of the grant date, subject to continued service and the award agreement (see footnotes F1–F2).
• Shares owned after transaction: Not specified in the filing.
• Footnotes: F1 explains each RSU equals a contingent right to one share upon vesting; F3 confirms no cash was paid for the grant.

Context
RSU grants are common as compensation and are not immediate purchases or sales — they represent potential future stock if the executive remains with the company and vesting conditions are met. The June 22 filing date is later than the typical two-business-day Form 4 deadline for reporting insider transactions, which investors may note but should consider in context (the filing itself discloses the award and vesting schedule).